(Q30356902)

20 June 2017

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. (English)

1 reference

20 June 2017

phase I clinical trial

0 references

1 reference

1 reference

Jiangtao Lin

1

1 reference

20 June 2017

Jiansan Zhang

2

1 reference

20 June 2017

Xiaoping Dong

3

1 reference

20 June 2017

Hanhua Fang

4

1 reference

20 June 2017

Jiangting Chen

5

1 reference

20 June 2017

Nan Su

6

1 reference

20 June 2017

Qiang Gao

7

1 reference

20 June 2017

Zhenshan Zhang

8

1 reference

20 June 2017

Yuxuan Liu

9

1 reference

20 June 2017

Zhihong Wang

10

1 reference

20 June 2017

Meng Yang

11

1 reference

20 June 2017

Ruihua Sun

12

1 reference

20 June 2017

Changgui Li

13

1 reference

20 June 2017

Su Lin

14

1 reference

20 June 2017

Mei Ji

15

1 reference

20 June 2017

Yan Liu

16

1 reference

20 June 2017

Xu Wang

17

1 reference

20 June 2017

John Wood

18

1 reference

20 June 2017

Zijian Feng

19

1 reference

20 June 2017

Yu Wang

20

1 reference

20 June 2017

Weidong Yin

21

1 reference

20 June 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

20 June 2017

1 reference

20 June 2017

368

1 reference

20 June 2017

991-997

1 reference

20 June 2017

9540

1 reference

Probable person-to-person transmission of avian influenza A (H5N1)

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Evolution of H5N1 avian influenza viruses in Asia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Selection of influenza vaccine strains and developing pandemic vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Development and evaluation of influenza pandemic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Trials of Influenza A/New Jersey/76 Virus Vaccine in Normal Children: An Overview of Age-Related Antigenicity and Reactogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

Safety, immunogenicity and efficacy of influenza vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

A Controlled Double-Blind Comparison of Reactogenicity, Immunogenicity, and Protective Efficacy of Whole-Virus and Split-Product Influenza Vaccines in Children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969294-5

7 January 2021

10.1016/S0140-6736(06)69294-5

Identifiers

DOI

1 reference

20 June 2017

1 reference